Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Shares Traded Last Trade
  396.00 3.82% 10,776.00 2,342,898 16:35:14
Bid Price Offer Price High Price Low Price Open Price
10,786.00 10,790.00 10,792.00 10,422.00 10,464.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,668.85 -195.96 5.92 1,653.0 166,933
Last Trade Time Trade Type Trade Size Trade Price Currency
18:00:17 O 300 10,702.33 GBX

Astrazeneca (AZN) Latest News

More Astrazeneca News
Astrazeneca Investors    Astrazeneca Takeover Rumours
Smart Money!
AZN is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 F&C INVESTMENT TRUST PLC 0.70% 2022-05-31

Astrazeneca (AZN) Discussions and Chat

Astrazeneca (AZN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Astrazeneca trades in real-time

Astrazeneca (AZN) Top Chat Posts

Astrazeneca Daily Update: Astrazeneca Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 10,380p.
Astrazeneca Plc has a 4 week average price of 9,399p and a 12 week average price of 9,399p.
The 1 year high share price is 11,000p while the 1 year low share price is currently 8,029p.
There are currently 1,549,116,129 shares in issue and the average daily traded volume is 2,469,742 shares. The market capitalisation of Astrazeneca Plc is £166,932,754,061.04.
philanderer: Downgrade. UBS cuts Astrazeneca to 'neutral' (buy) - price target 10,100 (10,500) pence
philanderer: and this.. 06/06/2022 | 07:38am EDT Already positive, the research from JP Morgan and its analyst James Gordon still consider the stock as a Buy opportunity. The target price is unchanged and still at GBX 12000.
mac15: I suspect there is growing acceptance that the international market opportunities for Azn are just as good as the mega companies such as Amazon ,Facebook, Microsoft etc. Being top of the FTSE is showing what's to come and that Azn is really a super stock. I also hold GSK and noticed the emarket finally spotting that there are huge opportunities for centres of excellence for big pharma and UK.
waldron: (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Monday its AZD8233 drug at 50-milligram dose lowered the levels of low-density lipoprotein cholesterol by 73% among people with high-risk hypercholesterolemia, meeting the main goal of a phase 2b study. The dose-ranging clinical trial, dubbed Etesia, evaluated AZD8233 at 15 mg, 50 mg and 90 mg doses administered monthly via subcutaneous injection within a 12-week period. Results showed that the drug also cut the PCSK9 enzyme levels by 89%, with sustained reductions observed over the dosing intervals. A decrease in PCSK9 raises LDL receptor levels, which in turn lowers cholesterol levels in the bloodstream, reducing the risk of developing heart disease. The safety, efficacy and tolerability of AZD8233 in hypercholesterolemia are being examined in the Solano phase 2b trial, with results expected later in the year. AstraZeneca gained nearly 1% on Monday's close. Price (GBP): £10142.00, Change: £+66.00, Percent Change: +0.66%
hjs: Growth - today is ex div date with a dividend of 145.3p so deduct that amount down today from the overall share price of AZN
beckers2008: HL View/Comment published on the 10th Feb: AstraZeneca's coronavirus vaccine has made it a household name worldwide, but the group's promise to sell the vaccine at cost ''during the pandemic'' means it's padded revenue but not profits. 2022 will pave a new road for the group's coronavirus medicines business--with vaccine sales waning and a monoclonal antibody treatment making up a larger proportion of sales, we can expect to see some of those dollars start to funnel through to the bottom line. This in addition to the potential growth runway coming from the Alexion acquisition have given management the confidence to increase shareholder returns, but remember dividends are variable and not guaranteed. Alexion brings rare disease treatments into the AZN fold, a fundamentally attractive area of the pharmaceutical market. The combination of Astra's massive distribution network and Alexion's specialized drugs should bring about a powerful windfall in the coming years. Rare diseases are, by definition, uncommon. In the past spending millions, perhaps billions, on researching a drug to treat a few tens of thousands of patients worldwide didn't make financial sense. Instead attention focused on treatments for common diseases, like asthma, with patients stretching into the tens of millions. As a result, only around 5% of designated rare diseases have approved treatments. More recently that attitude has shifted. While major diseases may have large markets, they also attract lots of competition. That means individual drugs companies can end up with a relatively small slice of a large pie. Competition in rare diseases is far lower - a drug company which develops a treatment for a previously unaddressed illness will likely end up serving the entire market and can probably attach a hefty price tag to boot. It's also unlikely a competitor will develop a more effective alternative, since competition is so much lower. Increased interest in the sector means the global rare disease market is forecasted to grow by a low double-digit percentage. Breaking into this market didn't come cheap, though. The acquisition more than doubled Astra's debt pile and sent free cash into the red. But this pales in comparison to the potential growth the combination offers. This is particularly true when it comes to emerging markets. Alexion's been primarily selling to the US and Europe, but under Astra's wing a greater proportion can be sold further afield. This is of course dependent on regulatory approval, but as AZN already has footholds in these markets it should make the process more efficient. Cash flow will be of utmost importance moving forward--debt now stands at more than 3 times underlying cash profits. With interest rates on the rise, we'd like to see that come down to more manageable levels. Shareholder returns are also marching higher, so the demands on cash are not insignificant. Any missteps in the Alexion integration, and the group will either have to saddle itself with more debt or trim the dividend. Overall we think Astra is pretty well placed. It's too early to say whether the Alexion deal will deliver on its potential, but a strong core business and the promise of rising coronavirus treatment profits are encouraging. If all goes to plan the future is bright.
beckers2008: AstraZeneca : Deutsche Bank Boosts AstraZeneca's PT, Keeps PT 10/11/2021 | 01:23pm BST (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) on Monday raised its price target on AstraZeneca (AZN.L, AZN.ST) to 105 pounds sterling ($143.19) from 102 pounds and maintained its buy rating. The Anglo-Swedish pharmaceutical company's shares increased marginally on Monday midday.
philanderer: Drug breakthroughs to drive AstraZeneca, says Berenberg Breast cancer drug Enhertu is expected to provide further upside in AstraZeneca (AZN) shares, says broker Berenberg. Analyst Luisa Hector retained her ‘buy’ recommendation and £95 target price on the shares, which closed up 2%, or 167p, at £86.66 on Monday. Hector said the share price had ‘largely recovered from its winter woes when the company’s Covid-19 vaccine and the proposed Alexion acquisition led to downward pressure’. She is expecting AstraZeneca to continue delivering returns on its research and development programme, in particular the investment in Enhertu, a medicine used to treat breast cancer that has spread to other parts of the body or cannot be removed by surgery. ‘Positive data readouts in the second half from pipeline assets such as Enhertu should drive further upside in the AstraZeneca share price as probabilities of success increase and sales are subject to upward revisions,’ she said. HTTPS://
arja: bad news announcement and AZN share price rockets - hard to understand the market at times !
stutes: I note how Alexion adr is around $170 level - below bid price. I don't buy into the recent increase while AZN share price remains below £85 to £100 range. Alexion needs AZN's cash to fund future r&d - time to renegotiate the bid price ?
Astrazeneca share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220625 20:35:41